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Abstract            
TBC1D1 is a Rab GTPase activating protein that is phosphorylated on Ser231 by the AMP-
activated protein kinase (AMPK) in response to intracellular energy stress. However, the in vivo 
role and importance of this phosphorylation event remains unknown. To address this question, 
we generated a mouse model harboring a TBC1D1Ser231Ala knockin mutation and found that the 
knockin mice developed obesity on a normal chow diet. Mechanistically, TBC1D1 is located on 
IGF1 storage vesicles, and the knockin mutation increases endocrinal and paracrinal/autocrinal 
IGF1 secretion in a Rab8a-dependent manner. Hypersecretion of IGF1 causes increased 
lipogenesis via activating the protein kinase B (PKB, also known as Akt)–mammalian target of 
rapamycin (mTOR) pathway in adipose tissues, which contributes to the development of obesity, 
diabetes and hepatic steatosis as the knockin mice age. Collectively, these findings demonstrate 
that the AMPK–TBC1D1 signaling nexus interacts with the PKB–mTOR pathway via IGF1 




Due to changes in diet and lifestyle, metabolic syndrome including obesity, type 2 
diabetes and non-alcoholic fatty liver disease are increasing in prevalence worldwide, putting a 
huge burden on modern society and motivating us to get better understanding of these syndromes 
and how to combat them. 
High energy intake and lack of physical activity can result in imbalances of energy 
metabolism and changed energy status of the body, which is monitored by the energy sensing 
kinase AMPK (Hardie et al., 2012). The AMPK holoenzyme is a heterotrimer, consisting of 
catalytic α (α1 and α2), regulatory β (β1 and β2) and γ (γ1, γ2 and γ3) subunits (Hardie et al., 
2012). AMPK is mainly activated through Thr172 phosphorylation in its catalytic T-loop by the 
upstream kinase LKB1 under energy stress conditions that increase the cellular AMP:ATP ratio 
(Hawley et al., 2003; Woods et al., 2003). The activation of AMPK also requires the v-ATPase–
Ragulator protein complex, which recruits the AXIN–LKB1–AMPK complex onto late 
endosomes where LKB1 phosphorylates AMPK (Zhang et al., 2014). AMPK can regulate both 
glucose and lipid metabolism by its phosphorylation of multiple substrates (Hardie, 2013). For 
instance, acetyl-CoA carboxylase (ACC), an enzyme important for fatty acid synthesis and 
oxidation, is regulated through an inhibitory phosphorylation by AMPK, which is essential for 
the control of lipid metabolism (Fullerton et al., 2013). AMPK can also control glucose uptake 
into skeletal muscle by promoting translocation of the glucose transporter 4 (GLUT4) from its 
intracellular storage sites onto plasma membrane (Kurth-Kraczek et al., 1999). Genetic ablation 
of individual AMPK subunits (α2, β2 or γ3) or LKB1, or overexpression of a dominant inhibitory 
mutant of AMPK in mouse, inhibit muscle glucose uptake in response to a pharmacological 
AMPK activator, 5-aminoimidazole-4-carboxamide riboside (AICAR), and partially inhibit 
glucose uptake in response to muscle contraction (Barnes et al., 2004; Jorgensen et al., 2004; Mu 
et al., 2001; Sakamoto et al., 2005; Steinberg et al., 2010). However, the mechanism by which 
AMPK promotes translocation of GLUT4 onto plasma membrane is not well understood. 
TBC1D1 is a Rab GTPase activating protein (RabGAP) and a R125W mutation on this 
protein has been linked to familial female obesity (Stone et al., 2006). A truncation or knockout 
of TBC1D1 confers leanness to mice fed on high fat diet with increased fatty acid oxidation in 
skeletal muscle (Chadt et al., 2008; Dokas et al., 2013). TBC1D1 has also been implicated in 
regulating trafficking of the glucose transporter 4 (GLUT4) (An et al., 2010; Peck et al., 2009) 
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while its deficiency causes a decreased expression level of GLUT4 in skeletal muscle (Chadt et 
al., 2008; Dokas et al., 2013; Stockli et al., 2015).  
We previously identified TBC1D1 as an AMPK substrate that is phosphorylated on Ser231 
by AMPK and interacts with 14-3-3 proteins upon Ser231 phosphorylation (Chen et al., 2008). 
However, the physiological role of this AMPK–TBC1D1 signal nexus remains elusive. In this 
study, we generated a TBC1D1Ser231Ala knockin mouse model to address the functions of 
TBC1D1 Ser231 phosphorylation in vivo.  
RESULTS 
Generation and characterization of the TBC1D1Ser231Ala knockin mice 
The TBC1D1Ser231Ala knockin mice were generated using the gene targeting strategy 
illustrated in Supplementary Fig. 1A. The expression levels of the TBC1D1Ser231Ala mutant 
proteins were normal, and there was no detectable alteration in the expression of the related 
RabGAP AS160 (also known as TBC1D4) in various tissues from the TBC1D1Ser231Ala knockin 
mice (Fig. 1A). As expected, the phosphorylation of Ser231 on TBC1D1 was not detectable in the 
tissues from the TBC1D1Ser231Ala knockin mice (Fig. 1A). The pharmacological AMPK activator 
metformin induced phosphorylation of AMPK in primary hepatocytes from the knockin mice to a 
similar extent as in wild-type cells (Fig. 1B). In contrast and as anticipated, metformin-stimulated 
TBC1D1 Ser231 phosphorylation was only detected in the lysates of wild-type, but not knockin, 
hepatocytes (Fig. 1B). The metformin-stimulated 14-3-3–TBC1D1 interaction assessed by 14-3-3 
overlay assays was diminished in the TBC1D1 immunoprecipitates from the knockin cell lysates 
as compared to the wild-type controls (Fig. 1B). Taken together, these data validate the suitability 
of the TBC1D1Ser231Ala knockin mice and their derived cells for studying the specific in vivo and 
in vitro function of TBC1D1 Ser231 phosphorylation. 
The TBC1D1Ser231Ala knockin mice developed obesity and displayed characteristics of 
metabolic syndrome when they aged 
We next monitored the growth of the TBC1D1Ser231Ala knockin mice and found that they 
became significantly heavier than the wild-type littermates from 5 weeks after birth 
(Supplementary Fig. 1B). The TBC1D1Ser231Ala knockin mice had longer bodies and tibias, and 
higher bone mineral density (BMD) than wild-types (Fig. 1C, Supplementary Fig. 1C-E). The 
growth plates of tibia from the TBC1D1Ser231Ala knockin mice were significantly elongated, in 
both the zone of proliferation and of hypertrophy (Supplementary Fig. 1F-G). The increased body 
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mass of the young knockins (less than 4-month-old) was accounted for by their significantly 
increased lean mass (Fig. 1D, Supplementary Fig. 2A-B). In contrast, the fat mass in the young 
TBC1D1Ser231Ala knockin mice was comparable to that of the wild-type littermate controls (Fig. 
1D, Supplementary Fig. 2A-B). However, although young TBC1D1Ser231Ala knockin mice 
contained a normal fat mass and enhanced lean mass, older TBC1D1Ser231Ala knockin mice 
became fatter, and had higher lean and fat masses than wild-types (Fig. 1E-F, Supplementary Fig. 
2C-D). Around five months of age was a transition period for increased fat mass in the 
TBC1D1Ser231Ala knockin mice. Consistent with the increased fat mass, adipocytes were markedly 
enlarged in the older TBC1D1Ser231Ala knockin mice (Fig. 1G-I). 
Obesity is a high risk factor for the development of type II diabetes and hepatic steatosis. 
The young TBC1D1Ser231Ala knockin mice had normal blood chemistry parameters including 
blood glucose, free fatty acid, triglyceride, total cholesterol and plasma insulin, and displayed 
normal glucose tolerance (Fig. 2A, and D-H). However, as these animals aged (~1-year-old), they 
developed hyperglycemia, hyperinsulinemia and hypercholesterolemia (Fig. 2D-F), and became 
glucose intolerant and insulin resistant (Fig. 2B-C). Furthermore, these mice developed hepatic 
steatosis, and their livers were significantly enlarged and contained larger lipid droplets (Fig. 2I-
L). 
Glucose uptake did not account for the obese phenotype of the TBC1D1Ser231Ala   knockin 
mice 
TBC1D1 has been implicated in regulating GLUT4 trafficking (An et al., 2010; Peck et al., 
2009), and its deficiency in mice decreases the GLUT4 expression and glucose uptake in skeletal 
muscle (Chadt et al., 2008; Dokas et al., 2013; Stockli et al., 2015). Therefore the TBC1D1Ser231Ala 
knockin mutation could potentially cause obesity via regulating glucose uptake. However, we 
found that GLUT4 expression was normal in skeletal muscle from the TBC1D1Ser231Ala knockin 
mice (Supplementary Fig. 3A). Furthermore, insulin- or contraction-stimulated glucose uptake 
rates in skeletal muscle from the TBC1D1Ser231Ala knockin mice were indistinguishable from those 
in wild-type controls (Supplementary Fig. 3B-C). In primary adipocytes, the TBC1D1Ser231Ala 
knockin mutation also did not affect insulin-stimulated GLUT4 translocation (Supplementary Fig. 
3D-F). 
Collectively, these data show that glucose uptake most likely did not account for the 
lower energy expenditure and obese phenotype of the TBC1D1Ser231Ala knockin mice. 
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Lipogenesis was increased in the adipose of the TBC1D1Ser231Ala knockin mice 
We next investigated whether altered adipogenesis, lipogenesis or lipolysis in the adipose 
might account for the obese phenotype of the TBC1D1Ser231Ala knockin mice. To this end, we 
analysed expression of key regulators for these processes in the adipose of the TBC1D1Ser231Ala 
knockin mice. The expression of adipose triglyceride lipase (ATGL), an important enzyme for 
lipolysis, was not altered in the adipose of the TBC1D1Ser231Ala knockin mice (Fig. 3A). Similarly, 
the expression of the adipogenic CEBPα and PPARγ genes remained normal in the adipose of the 
TBC1D1Ser231Ala knockin mice (Fig. 3A-B). In contrast, the expression of fatty acid synthase 
(FASN), a key enzyme for lipogenesis, was significantly upregulated in the adipose of the 
TBC1D1Ser231Ala knockin mice at both mRNA and protein levels, despite the normal expression of 
SREBP1 that is an upstream transcriptional regulator for FASN (Fig. 3A-B). It has recently been 
shown that lipin1, a downstream target of mTOR, can downregulate SREBP1 activity in the 
nucleus and consequently control the expression of FASN in adipose (Peterson et al., 2011). The 
entry of lipin1 into the nucleus is under control of its phosphorylation by mTOR, and this 
phosphorylation promotes lipogenesis by releasing the inhibitory effect of lipin1 on SREBP1 and 
consequently upregulating FASN expression (Peterson et al., 2011). Interestingly, 
phosphorylation of lipin1 was significantly upregulated in the adipose of the TBC1D1Ser231Ala 
knockin mice (Fig. 3C), suggesting that upregulation of FASN in these mice was due to enhanced 
SREBP1 activity via lipin1 phosphorylation. Consistently, phosphorylation of PKB, tuberous 
sclerosis 2 (TSC2, also known as tuberin) and mTOR were all increased in the adipose of the 
TBC1D1Ser231Ala knockin mice (Fig. 3C). This PKB activation in the adipose of the 
TBC1D1Ser231Ala knockin mice selectively regulated the phosphorylation of TSC2–mTOR, but not 
AS160, which is a key regulator for insulin-stimulated glucose uptake (Fig. 3C). We further 
found that the phosphorylation of PKB, TSC2 and mTOR was also upregulated in skeletal 
muscle and liver of the TBC1D1Ser231Ala knockin mice (Supplementary Fig. 4). 
Together, these data show that the PKB–TSC2–mTOR–lipin1 pathway is activated in the 
TBC1D1Ser231Ala knockin mice, which can increase lipogenesis through upregulation of FASN. 
Plasma IGF1 levels were elevated in the TBC1D1Ser231Ala knockin mice 
We next sought to find out how the TBC1D1Ser231Ala knockin mutation causes the 
activation of the PKB–TSC2–mTOR pathway. Considering the overgrowth phenotype of the 
TBC1D1Ser231Ala knockins, we surmised that the levels of IGF1, a key growth promoter that 
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activates the PKB–TSC2–mTOR pathway in multiple tissues, might be elevated. Indeed, plasma 
IGF1 levels were significantly higher in both male and female TBC1D1Ser231Ala knockin mice 
compared with their wild-type littermates (Fig. 4A, Supplementary Fig. 2G). In contrast, the 
plasma levels of the IGF1-binding protein IGFBP3 were normal in the knockin mice (Fig. 4B, 
Supplementary Fig. 2H). The expression levels of IGF1 and IGFBP3 were normal at both the 
mRNA and protein levels within the liver (Fig. 4D-G), which is the major endocrinal production 
site for these proteins. Expression of IGF1 and IGFBP3 in the liver is under control of growth 
hormone (GH). Consistent with unaltered expression of IGF1 and IGFBP3 in the liver, plasma 
GH levels were normal in the TBC1D1Ser231Ala knockin mice (Fig. 4C, Supplementary Fig. 2I). 
We further found that the hepatic expression and phosphorylation of the GH receptor (GHR) and 
its downstream mediator, JAK2, were unaltered in TBC1D1Ser231Ala knockin mice (Fig. 4D). 
These data show that plasma IGF1 levels were selectively elevated in the TBC1D1Ser231Ala 
knockin mice, but with no alteration in the action of GH on its hepatic expression. 
TBC1D1 colocalizes with IGF1 vesicles and regulates IGF1 secretion 
IGF1 is synthesized and temporarily stored within vesicles in hepatocytes, and then 
secreted into the bloodstream. Interestingly, when TBC1D1 and IGF1 were co-expressed in 
human liver carcinoma HepG2 cells, the two proteins largely co-localized with each other 
(Supplementary Fig. 5A). We further found that endogenous TBC1D1 was localized on the IGF1 
storage vesicles in primary hepatocytes (Fig. 5A) and in myotubes (Supplementary Fig. 5B). 
Together, these data suggest that TBC1D1 might be involved in the regulation of IGF1 secretion. 
Indeed, knockdown of TBC1D1 significantly decreased IGF1 secretion rates in primary 
hepatocytes with no alteration in IGF1 expression (Fig. 5B-C). Furthermore, in primary 
hepatocytes from our previously reported TBC1D1 knockout mice (Ducommun et al., 2012), 
IGF1 secretion rates were also significantly lower than those of the wild-type controls, despite 
normal hepatic IGF1 expression (Fig. 5D-E).  
The TBC1D1Ser231Ala knockin mutation increases both endocrinal and paracrinal/autocrinal 
IGF1 secretion 
Consistent with the elevated levels of plasma IGF1 in the TBC1D1Ser231Ala knockin mice, 
IGF1 secretion rates of primary hepatocytes from these mice were significantly higher than those 
of wild-type cells under unstimulated conditions (Fig. 5F). The widely-used AMPK activators, 
metformin and AICAR, significantly decreased IGF1 secretion rates of wild-type hepatocytes 
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(Fig. 5F). While the rates of IGF1 secretion by TBC1D1Ser231Ala knockin hepatocytes decreased in 
response to metformin or AICAR, these secretion rates still remained significantly higher than 
those of wild-type cells treated with these drugs (Fig. 5F). We confirmed that the activation of 
AMPK by AICAR and metformin was comparable in primary hepatocytes from the knockin mice 
and in wild-type cells, with no effect on IGF1 protein expression (Fig. 5J). We further found that 
the TBC1D1Ser231Ala knockin mutation also affected paracrinal/autocrinal IGF1 secretion. In 
primary chondrocytes, IGF1 secretion rates were significantly higher in the knockin cells than 
those in the wild-type cells under both unstimulated and AICAR-treated conditions (Fig. 5G and 
K). Similarly, IGF1 secretion rates were also significantly increased in the knockin adipocytes 
and isolated skeletal muscle ex vivo, compared with the wild-type cells or tissues (Fig. 5H-I). 
Consistent with normal plasma levels of IGFBP3, secretion of IGFBP3 was unaltered in 
primary hepatocytes from the TBC1D1Ser231Ala knockin mice (Supplementary Fig. 6). These data 
show that the TBC1D1Ser231Ala knockin mutation selectively affects IGF1 secretion. 
Inhibition of IGF1 secretion or action blunted the hyperactivation of the PKB pathway in 
primary cells from the TBC1D1Ser231Ala knockin mice 
We next sought to establish a causal relationship between the hypersecretion of IGF1 and 
the activation of the PKB–TSC2–mTOR pathway in the TBC1D1Ser231Ala knockin mice. To this 
end, we first employed the non-IGF1 secretive cell line HEK293 (Supplementary Fig. 7A) to 
investigate the effect of the TBC1D1Ser231Ala mutation on the activation of the PKB-TSC2-mTOR 
pathway. Over-expression of human TBC1D1 wild-type or TBC1D1Ser231Ala mutant proteins in 
HEK293 cells did not affect the PKB–TSC2–mTOR pathway (Supplementary Fig. 7B), 
suggesting that the activation of the PKB–TSC2–mTOR pathway caused by the TBC1D1Ser231Ala 
mutation requires IGF1 secretion. We next employed primary adipocytes and hepatocytes 
isolated from these knockin mice, in which the PKB–TSC2–mTOR pathway was activated under 
unstimulated conditions (Supplementary Fig. 7C-F). It is well known that activation of AMPK 
can inhibit mTOR through phosphorylation of TSC2 and raptor (Gwinn et al., 2008; Inoki et al., 
2003). Inhibition of mTOR can decrease the serine phosphorylation of insulin receptor substrate-
1 (IRS-1) and consequently increase its tyrosine phosphorylation that results in PKB activation 
(Tzatsos and Kandror, 2006). Consistent with these reports, AICAR could inhibit the 
phosphorylation of mTOR and consequently activate PKB in wild-type adipocytes (Fig. 6A-C). 
Both PKB and mTOR phosphorylation were again higher in TBC1D1Ser231Ala knockin adipocytes 
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than wild-type cells under unstimulated conditions. As in wild-type cells, AICAR could inhibit 
mTOR phosphorylation in TBC1D1Ser231Ala knockin adipocytes. However, in contrast to the 
increase of PKB phosphorylation in wild-type adipocytes, PKB phosphorylation was decreased in 
TBC1D1Ser231Ala knockin adipocytes upon AICAR stimulation (Fig. 6A-C), which is most likely 
due to inhibition of IGF1 secretion by AICAR. 
We further used an IGF1 receptor inhibitor, picropodophyllin (PPP) (Girnita et al., 2004), 
to treat primary hepatocytes from the wild-type and TBC1D1Ser231Ala knockin mice. The 
phosphorylation of PKB was significantly increased in TBC1D1Ser231Ala knockin hepatocytes 
under untreated conditions (Fig. 6D-E). Morover, blocking the IGF1 receptor with PPP strongly 
decreased PKB phosphorylation in TBC1D1Ser231Ala knockin, but not wild-type, hepatocytes (Fig. 
6D-E). These findings suggest that hyperactivation of PKB in TBC1D1Ser231Ala knockin 
hepatocytes was most likely due to hypersecretion of IGF1. The reason for the unaltered PKB 
phosphorylation in wild-type cells upon PPP treatment is not clear, however we speculate that 
this basal PKB activation in wild-type hepatocytes is probably not elicited through the IGF1 
receptor. 
Together, these data strongly suggest a causal relationship between hypersecretion of 
IGF1 and activation of the PKB–TSC2–mTOR pathway in the TBC1D1Ser231Ala knockin mice. 
Rab8a plays a key role downstream of the TBC1D1 in regulating IGF1 secretion 
We then sought to find out how TBC1D1 and its Ser231 phosphorylation regulate IGF1 
secretion. IGF1 secretion rates were largely restored when a human recombinant TBC1D1 was 
expressed in the TBC1D1 knockout hepatocytes (Fig. 7A). Unlike the endogenous TBC1D1, the 
expressed human TBC1D1 was hypophosphorylated, and the expression of human 
TBC1D1Ser237Ala mutant protein (Ser237 on human TBC1D1 corresponds to Ser231 on the mouse 
protein) did not increase IGF1 secretion rates over-and-above those achieved with the wild-type 
TBC1D1 (Fig. 7A). Interestingly, the expression of a GAP-deficient TBC1D1 mutant (Roach et 
al., 2007) could not restore IGF1 secretion rates (Fig. 7A), suggesting that the GAP activity of 
TBC1D1 is required for IGF1 secretion. We next investigated which Rab(s) downstream of 
TBC1D1 mediates IGF1 secretion by down-regulating four known in vitro TBC1D1 substrates, 
namely Rab2a, Rab8a, Rab10 and Rab14 (Roach et al., 2007). Knockdown of Rab8a caused a 
significant decrease in IGF1 secretion rates in wild-type primary hepatocytes (Fig. 7B-C) while 
down-regulation of Rab2a, Rab10 and Rab14 had no significant effect (Supplementary Fig. 8). 
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We also found that Rab8a largely colocalized with IGF1 in primary hepatocytes (Fig. 7D). 
Furthermore, knockdown of Rab8a normalized IGF1 secretion in primary hepatocytes from the 
TBC1D1Ser231Ala knockin mice (Fig. 7E-F), suggesting that regulation of IGF1 secretion by the 
TBC1D1 Ser231 phosphorylation requires Rab8a. Overexpression of the wild-type Rab8a and a 
GDP-bound Rab8aT22N mutant, but not a GTP-bound Rab8aQ67L mutant, could restore IGF1 
secretion in the TBC1D1 knockout hepatocytes (Fig. 7G-H). In an in vitro assay, 
immunoprecipitated recombinant hTBC1D1 displayed significant GAP activity towards Rab8a 
and enhanced the GTPase activity of Rab8a. The GAP activity of hTBC1D1 towards Rab8a was 
inhibited by its cellular phosphorylation in response to AMPK activator phenformin, and in 
contrast was enhanced by Ser237Ala mutation (Fig. 7I-J). These data suggest that the GDP-
bound Rab8a promotes IGF1 secretion downstream of TBC1D1. Consistent with this proposal, 
we found that knockdown of Rabin8, a guanine nucleotide exchange factor (GEF) for Rab8a 
(Hattula et al., 2002), promoted IGF1 secretion in primary hepatocytes (Fig. 7K-L). Together, 
these data show that TBC1D1 and its Ser231 phosphorylation control IGF1 secretion by regulating 
Rab8a. 
DISCUSSION 
Our findings shed light on how energy status regulates lipogenesis and are consistent with 
a model in which the AMPK–TBC1D1 signaling nexus controls lipogenesis by regulating 
endocrinal and paracrinal/autocrinal IGF1 secretion. Inhibition of TBC1D1 Ser231 
phosphorylation increases lipogenesis and consequently causes obesity in mice most likely due to 
hypersecretion of IGF1 and hyperactivation of the PKB–TSC2–mTOR pathway.  
It has long been recognized that the energy and nutrient sensors, AMPK and mTOR, play 
opposing roles in governing cell growth in response to varying energy status (Inoki et al., 2003; 
Sarbassov et al., 2005). Energy deficiency activates AMPK, which in turn phosphorylates 
proteins including TSC2 and raptor. Phosphorylation of TSC2 leads to inhibition of the small 
GTPase Rheb, while phosphorylated raptor binds to the dimeric phosphoprotein-binding 14-3-3 
proteins, and both of these mechanisms lead to inhibition of mTOR. The AMPK–TSC2–Rheb–
mTOR and AMPK–raptor–mTOR pathways restrict cell growth in response to energy shortage 
(Gwinn et al., 2008; Inoki et al., 2003). Besides this opposing effect on growth, both AMPK and 
mTOR regulate lipogenesis. AMPK can phosphorylate ACC and thereby inhibit fatty acid 
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synthesis (Fullerton et al., 2013). In contrast, mTOR can phosphorylate lipin1 and the latter can 
promote lipogenesis by enhancing SREBP1 activity (Peterson et al., 2011).  
Our findings reveal a previously unrecognized layer of regulation, involving IGF1 as a 
systemic signal that links these two signaling pathways to control lipogenesis in response to 
energy status. In our model, we propose that energy deficiency activates AMPK, which inhibits 
both endocrinal and paracrinal/autocrinal IGF1 secretion via phosphorylation of TBC1D1 and 
possibly other regulators of IGF1 secretion. Decreased endocrinal and paracrinal/autocrinal IGF1 
secretion results in hypoactivation of the PKB–mTOR pathway, which may contribute to a 
decline in lipogenesis in adipose tissues. When energy is sufficient, AMPK activity and TBC1D1 
phosphorylation decrease in the body, which promotes endocrinal and paracrinal/autocrinal IGF1 
secretion. The elevated IGF1 activates PKB–mTOR signaling, which may promote lipogenesis in 
adipose tissues. Our findings not only elucidate the complexity of the regulatory mechanism 
linking energy status with lipogenesis but also provide novel potential targets for drug discovery 
to combat with obesity. These findings may also help to elucidate the therapeutic mechanisms for 
the anti-diabetic drug metformin.  Though metformin has been used as the frontline anti-diabetic 
drug for many years (Wong et al., 2014), its therapeutic mechanisms are still not fully 
understood. Our observation that metformin inhibits IGF1 secretion opens a new possibility that 
this drug may regulate lipogenesis in the adipose through modulating IGF1 secretion. 
Genetic evidence has suggested that TBC1D1 is linked to obesity although the molecular 
mechanisms are not fully understood. For instance, the TBC1D1R125W mutation is a candidate for 
obesity susceptibility in human patients (Stone et al., 2006), while deficiency of TBC1D1 
protects mice from diet-induced obesity (Chadt et al., 2008; Dokas et al., 2013). Serum IGF1 
levels are associated with adiposity (Gayet et al., 2004): lower serum IGF1 levels in several 
mouse models correlate with reduced adipose tissue (Hesse et al., 2012; Wang et al., 2014), while 
higher IGF1 levels in the blood are associated with increased adiposity in a liver-specific PTPN2 
knockout mouse (Gurzov et al., 2014). Our findings provide one mechanism linking TBC1D1 
Ser231 phosphorylation to lipogenesis by controlling IGF1 secretion, which contributes to the 
development of obesity, type II diabetes and hepatic steatosis as the knockin mice age.  
Clearly, TBC1D1 has other functions, and can regulate GLUT4 expression and fatty acid 
oxidation in skeletal muscle (Chadt et al., 2008; Dokas et al., 2013; Stockli et al., 2015). 
TBC1D1 can be phosphorylated on multiple sites besides Ser231 (Chen et al., 2008), and 
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electroporation of a TBC1D1-4P mutant (in which Ser231, Thr499, Thr590, and Ser621 are mutated 
to Ala) into skeletal muscle decreases contraction-stimulated glucose uptake (An et al., 2010). 
Since our study does not support a role for TBC1D1 Ser231 phosphorylation in regulating GLUT4 
expression or trafficking under the conditions tested here, it is possible that other phosphorylation 
sites on TBC1D1 might be important for contraction-stimulated muscle glucose uptake. 
Our knowledge of the regulation of IGF1 secretion is surprisingly sparse, despite the 
many essential roles of this hormone and the intense study of how its downstream signaling 
pathways regulate cellular growth (Maggio et al., 2013). Besides the regulatory mechanism we 
describe here, the only previously known mechanism involves a calcium sensor synaptotagmin-
10 that regulates activity-dependent IGF1 secretion in olfactory bulb neurons (Cao et al., 2011). 
Synaptotagmin-10 can bind to phospholipid and the SNARE-complex in a calcium-dependent 
manner, which triggers exocytosis. Given the important functions of IGF1 and potential for 
modulating its release for therapeutic purposes, we must elucidate the regulation of IGF1 
secretion in more detail in future. There are several open questions stemming from our model, 
which deserve to be addressed. For instance, what are upstream regulators of AMPK that control 
IGF1 secretion under energy deficient conditions? Upon energy stress, the late 
endosomal/lysosomal protein complex v-ATPase–Ragulator recruits AXIN–LKB1–AMPK onto 
late endosome, which consequently activates AMPK (Zhang et al., 2014). We are therefore 
intrigued to know whether the v-ATPase–Ragulator–AXIN–LKB1 complex controls IGF1 
secretion through activating AMPK in response to energy deficiency. Another question is how 
Rab8a regulates IGF1 secretion in a manner that is dependent on its GDP-bound form. Although 
Rabs usually regulate their effector proteins in their GTP-bound forms, there are precedents that 
GDP-bound forms of Rabs can have biological functions. For instance, Rab8a has recently been 
shown to promote fusion of lipid droplets in its GDP-bound form (Wu et al., 2014). Identification 
of downstream effector(s) for the GDP-bound form of Rab8a will help to elucidate the 
mechanism how Rab8a regulates IGF1 secretion and deepen our understanding of this process. 
MATERIALS AND METHODS 
Materials 
Recombinant human insulin was purchased from Novo Nordisk (Denmark), IGF1 from 
Cell Signaling Technology (Danvers, MA, USA), AICAR from Toronto Research Chemicals 
(Toronto, Ontario, Canada), and metformin from Sigma-Aldrich (St. Louis, Missouri, USA). 
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Microcystin-LR was from Enzo Life Sciences (Farmingdale, NY, USA). Picropodophyllin (PPP) 
was from Selleck Chemicals (Shanghai, China). Protein G-Sepharose was from GE Healthcare 
(Little Chalfont, Buckinghamshire, UK), and NHS-digoxygenin (NHS-DIG) from Roche 
Diagnostics (Basel, Switzerland). 2-deoxy-D-[1,2-3H(N)]glucose and D-[1-14C]-mannitol were 
from PerkinElmer. All other chemicals were from Sigma-Aldrich or Sangon Biotech (Shanghai, 
China). 
Antibodies 
The rabbit antibody that recognises phosphorylated Ser231 on TBC1D1 (#07-2268) and 
the mouse antibody against IGF1 (#05-172) were from Millipore. The anti-GH antibody (T-20, 
sc-10365), anti-Rab14 (sc-98610) and anti-GHR (S-19, sc-10355) were from Santa Cruz. The 
rabbit antibodies that recognise phosphorylated Thr172 on AMPK (#2531), phosphorylated Ser212 
on ACC2 (#3661), phosphorylated Ser473 on PKB (#9271), phosphorylated Ser127 on YAP 
(#4911), anti-AMPK alpha subunit (#2532), anti-ACC (#3676), anti-PKB (#9272), anti-TBC1D1 
(#4629), anti-Rab8a (#6975), anti-Rab10 (#4262), PhosphoPlus Jak2 antibody duet (#8224), 
PPARγ regulated fatty acid metabolism antibody sampler kit (#8660), fatty acid and lipid 
metabolism antibody sampler kit (#8335) and mTOR substrates antibody sampler kit (#9862) 
were from Cell Signaling Technology. The rabbit anti-IGF1, anti-Rab2 and anti-IGFBP3 
antibodies were from Proteintech. 
Generation of the TBC1D1Ser231Ala knockin mouse 
The TBC1D1Ser231Ala knockin mouse was generated by the transgenic service facility at 
University of Dundee following the targeting strategy outlined in Fig. 1A. Briefly, the Ser231 (the 
surrounding sequence is MRKSFsQP, Ser231 shown in lower case bold) on TBC1D1 was mutated 
to alanine by point mutagenesis. The fourth exon (numbering according to Tbc1d1-002 
ENSMUST00000121370) harbouring the point mutation was flanked by loxP sites to facilitate its 
excision by Cre recombinase. The TBC1D1Ser231Ala knockin mouse was generated after in vivo 
Flp-mediated removal of selection marker, Neo gene, which was flanked by frt sites. 
Mouse husbandry and genotyping 
The Ethics Committees initially at University of Dundee, and latterly at Nanjing 
University approved all animal studies, breeding and husbandry. The TBC1D1Ser231Ala knockin 
mice were back-crossed with C57BL6 for at least 8 generations before experiments. Mice were 
housed with a light/dark cycle of 12 h, and free access to food and water unless stated. 
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Genotyping of the TBC1D1Ser231Ala knockin and wild-type alleles was performed by PCR using 
the following primers: 5’- TGGTTTACTGTGGCAGGAGGCAT-3’ and 5’-
CACTGGGCTTTGTCTCTGATACTG-3’. The TBC1D1 knockout mice were genotyped as 
previously described (Ducommun et al., 2012). 
Body composition analysis 
Mouse body composition was determined via dual-energy X-ray absorptiometry (DEXA) 
using a Lunar PIXImus II densitometer (GE Healthcare). Mice were anaesthetized with 
isoflurane, and images were taken with the PIXImus II densitometer and analyzed using the 
PIXImus II software following the manufacturer’s instructions. 
Glucose tolerance test and insulin tolerance test 
After being denied access to food for 4 h (prior to insulin tolerance test) or overnight (16 
h; for glucose tolerance test), mice were tail bled for measurement of basal blood glucose levels 
using a Breeze 2 glucometer (Bayer). Afterwards, mice were intraperitoneally injected either with 
a bolus of glucose (2 mg glucose per g of body weight) for intraperitoneal glucose tolerance test, 
or with a bolus of insulin (0.75 mU insulin per g of body weight) for insulin tolerance tests. In 
case of the oral glucose tolerance test, mice were orally administered via gavage with a bolus of 
glucose (1.5 mg glucose per g of body weight). Blood glucose levels were subsequently 
determined at the indicated times. 
Blood chemistry and hormone analysis 
Blood glucose levels were determined using a Breeze 2 glucometer (Bayer). For other 
blood parameters, blood was collected from tail veins of random-fed or overnight fasted mice. 
Plasma IGF1, IGFBP3, GH and insulin levels were determined using an IGF1 ELISA kit (Cat 
No. ELM-IGF1-1, RayBiotech Inc, USA), IGFBP3 ELISA kit (Cat No. ELM-IGFBP3, 
RayBiotech Inc, USA), GH ELISA kit (EZRMGH-45K, EMD Millipore, USA) and insulin 
ELISA kit (EZRMI-13K, EMD Millipore, USA), respectively. Plasma free fatty acid, triglyeride 
and total cholesterol levels were determined using a Wako LabAssay NEFA kit (294-63601), 
LabAssay Triglyceride (290-63701) and LabAssay Cholesterol kit (294-65801) (Wako 
Chemicals USA, Inc.). 
Primary cell isolation and IGF1 secretion assay 
Primary mouse hepatocytes were isolated using a collagenase-based method and cultured 
as previously described (Patel et al., 2014). Hepatocytes from preparations with a cell viability ≥ 
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90% were seeded in 12-well plates at a density of 1.25 x 105 per well in a plating medium (M199 
with GlutaMAXTM supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.1% 
bovine serum albumin (BSA), 10% (v/v) foetal bovine serum, 10 nM insulin, 200 nM 
triiodothyronine, 500 nM dexamethasone) for 4 h and then incubated overnight (16 h) in a 
recovery medium (M199 with GlutaMAXTM supplemented with 100 U/ml penicillin, 0.1 mg/ml 
streptomycin and 10% (v/v) foetal bovine serum). The next morning, cells were washed once 
with PBS and incubated in a serum-starvation medium (M199 with GlutaMAXTM supplemented 
with 100 U/ml penicillin and 0.1 mg/ml streptomycin) for 4 h. After serum-starvation, cells were 
washed once with PBS and further incubated in an assay medium (M199 with GlutaMAXTM 
supplemented with 100 U/ml penicillin and 0.1 mg/ml streptomycin) for another 4 h in the 
presence or absence of stimuli. The assay medium was collected for measurements of IGF1 using 
an ELISA kit (Cat No. ELM-IGF1-1, RayBiotech Inc, USA), and the cells were lysed and used 
for Western blot analysis. 
Primary mouse chondrocytes were isolated from articular cartilage of hind legs of 2- to 7-
day-old pups as previously described (Archer et al., 1990). Briefly, cartilage was digested in the 
digestion medium (DMEM/F12 supplemented with 2.5% FBS, 1% penicillin/streptomycin and 1 
mg/ml type 2 collagenase), and chondrocytes were filtered and washed with DMEM/F12 
medium. Chondrocytes were then cultured overnight in DMEM/F12 medium supplemented with 
10% FBS and 1% penicillin/streptomycin. Afterwards, chondrocytes were changed to fresh assay 
medium for another 4 h and the assay medium was collected for IGF1 measurement. 
Primary preadipocytes were isolated from epididymal fat pad and differentiated into 
adipocytes as previously described (Wu et al., 2014). On day 6 after initiation of differentiation, 
adipocytes were changed to fresh assay medium for another 4 h and the assay medium was 
collected for IGF1 measurement. 
For IGF1 secretion in ex vivo skeletal muscle, isolated EDL muscles were incubated in 
DMEM medium for 2 h, and the medium was collected for IGF1 measurement. 
Cell culture and transfection 
Human embryonic kidney HEK293 cells and human liver carcinoma HepG2 cells were 
obtained from the Cell Resource Center, Chinese Academy of Medical Sciences and Peking 
Union Medical College (China). Cells were cultured in DMEM medium containing 10% (v/v) 
foetal bovine serum, and subjected to tests for mycoplasma contamination on a regular basis. 
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PEI-mediated transfection of cells was carried out as previously described (Chen et al., 2014). 
siRNAs used for knockdown experiments are as previously described (Wu et al., 2014), and 
listed in Supplemental Table 1. 
In situ muscle contraction 
In situ muscle contraction was performed as previously described (Ducommun et al., 
2012). Briefly, electrodes were attached to surgically-exposed sciatic nerves of both hindlimbs of 
mice anaesthetised with sodium pentobarbital (90 mg/kg of body weight, administered 
intraperitoneally). Electrical stimulation of sciatic nerves to induce in situ contraction of hindlimb 
muscles was performed on one leg for 10 min while the other leg served as sham-operated control 
(basal). After contraction, mice were terminated by cervical dislocation, and EDL from both legs 
were isolated and used for glucose uptake. 
Muscle incubation and glucose uptake ex vivo 
Isolated soleus or EDL muscles were incubated with or without stimuli in KRB buffer that 
was continuously gassed with 95% O2/5% CO2 for 50 min. Muscles were then either snap-frozen 
in liquid nitrogen for subsequent biochemical studies or used for glucose uptake as previously 
described (Chen et al., 2011). Briefly, glucose uptake was carried out in KRB buffer containing 2-
deoxy-D-[1,2-3H(N)]glucose for another 10 min with or without stimuli. After termination of the 
assay, muscles were blotted dry, snap-frozen in liquid nitrogen, weighed and lysed. Radioisotopes 
in muscle lysates were measured using a Tri-Carb 2800TR scintillation counter (PerkinElmer). 
Liver triglyceride measurement 
Liver triglyceride content was measured as previously described (Norris et al., 2003). 
Briefly, frozen liver chunks were saponified in ethanolic KOH, and the extracts were subsequently 
neutralized. The resultant free glycerol was determined with the Free Glycerol Reagent (F6428, 
Sigma-Aldrich) using glycerol (G7793, Sigma-Aldrich) as standard for calculation. 
Tissue lysis and immunoprecipitation 
Mouse tissues were homogenized as previously described (Ducommun et al., 2012), and 
protein concentrations of tissue lysates were determined using Bradford reagent (Thermo 
Scientific). 
The anti-TBC1D1 antibody (1 µg antibody/mg cell lysate protein) was used to 
immunoprecipitate TBC1D1 proteins from cell lysates. Briefly, lysates were mixed with the 
antibody-coupled protein G-Sepharose. After overnight incubation at 4oC, the suspension was 
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centrifuged to sediment and non-specific binding proteins were then washed off from the resins. 
The immunoprecipitates were extracted in SDS sample buffer for subsequent analysis via 
Western blot. 
Rab8a GTPase activity measurement 
The GTPase activity of recombinant GST-Rab8a was determined through measuring 
phosphate released during reaction in the presence or absence of immunoprecipitated HA-
hTBC1D1 as previously described (Li et al., 2015). 
Western blot and 14-3-3 overlay 
Proteins were electrophoretically separated on SDS-PAGE gels, and subsequently 
immunoblotted onto nitrocellulose membranes that were blocked in milk and incubated at 4oC for 
16 h using the indicated antibodies or digoxygenin-labelled 14-3-3 proteins in case of 14-3-3 
overlay. Detection was carried out using horseradish-peroxidase-conjugated secondary antibodies 
(Promega) and ECL® (enhanced chemiluminescence reagent; GE Healthcare). 
RNA isolation and QPCR 
Total RNA was isolated using the TRIzol® Reagent (Life Technologies) and reverse-
transcribed into cDNA using a PrimeScript® RT reagent kit (DRR047A, TaKaRa). The 
expression levels of target genes were determined via QPCR using an Applied Biosystems® 
StepOnePlusTM Real-Time PCR system (Life Technologies) and the primers listed in 
Supplementary Table 2. 
Immunofluorescence staining and imaging 
Immunofluorescence staining was carried out as previously described (Chen et al., 2014). 
Briefly, primary hepatocytes fixed in paraformaldehyde were sequentially incubated with primary 
antibodies and Alexa Fluor®-conjugated or Cy3/Cy5-conjugated secondary antibodies. After 
decoration with the antibodies, slides were mounted, photographed with a Leica confocal 
microscope, and representative images are shown. 
Statistical analysis 
Data were checked for normal distribution and similar variance. Unless stated, data were 
analyzed via two-sided student’s t-test, and differences were considered statistically significant at 
P0.05. For animal experiments, number of animals was kept as small as possible, and yet still 
resulted in statistically meaningful data. 
Reproducibility 
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Results for animal experiments are representative of at least two similar experiments. 
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Figure 1    Generation and characterization of the TBC1D1Ser231Ala knockin mice 
A. TBC1D1 expression and Ser231 phosphorylation and AS160 expression in various tissues of 
the TBC1D1Ser231Ala knockin mice. 
B. Ser231 phosphorylation and 14-3-3 binding of TBC1D1 isolated from primary hepatocytes that 
had been treated with metformin. 
C. Representative picture of the male TBC1D1Ser231Ala knockin mice at 52 weeks of age. The bar 
indicates 1 cm in length. 
D-F. Body composition of the male TBC1D1Ser231Ala knockin mice measured at the age of 14 
weeks (D, WT: n=18; KI: n=19), 20-22 weeks (E, WT: n=15; KI: n=15) and 52 weeks (F, WT: 
n=8; KI: n=9). 
G-I. Histology (G) and cell size (H and I) of the adipose from the wild-type and TBC1D1Ser231Ala 
knockin male mice. Bars indicate 50 μm in length. The sizes of wild-type cells were set to one, 
and the sizes of knockin cells were then normalized with the respective wild-type cells. The 
numbers shown in the bar graphs refer to the number of cells measured in the experiments. 
The data are given as the mean ± SEM, and the asterisk indicates p < 0.05. 
Figure 2    Insulin sensitivity, blood chemistry and hepatic lipid contents in the 
TBC1D1Ser231Ala knockin mice 
A-B. Oral glucose tolerance test in the male TBC1D1Ser231Ala knockin mice at age of 14 weeks 
(A, WT: n=5; KI: n=7) and 40 weeks (C, WT: n=6; KI: n=7). The values show the glucose area 
under the curve during glucose tolerance test. 
C. Insulin tolerance test in the male TBC1D1Ser231Ala knockin mice at age of 32 weeks. The data 
are relative to the basal blood glucose levels before insulin injection. n=5. 
D-H. Blood glucose (D), plasma insulin (E), total cholesterol (F), NEFA (G) and triglyceride (H) 
in the overnight-fasted male TBC1D1Ser231Ala knockin mice at 4.5 (young) and 12 (old) months of 
age. WT: n=7; KI: n=9. 
I-L. Liver morphology and histology (I), fresh weight (J), triglyceride (K), lipid droplet (LD) size 
distribution (L) in the old male TBC1D1Ser231Ala knockin mice and wild-type littermates (13-
months-old). Bars for liver morphology indicate 0.5 cm in length while those for liver sections 
indicate 20 μm in length. n=8-9. 
The data are given as the mean ± SEM, and the asterisk indicates p < 0.05. 
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Figure 3   Lipogenesis in the TBC1D1Ser231Ala knockin mice 
A. Protein expression of FASN, ATGL and PPARγ, and phosphorylated and total AMPK were 
measured in the adipose from the wild-type and TBC1D1Ser231Ala knockin male mice (16-week-
old) using GAPDH as a loading control. 
B. Phosphorylated and total lipin1, PKB, TSC2, mTOR, AS160 and TBC1D1 were measured in 
the adipose from the TBC1D1Ser231Ala knockin mice and wild-type littermates (16-week-old) 
using GAPDH as a loading control. 
C. mRNA expression of Fasn, Srebp1, PPARγ and Cebpα in the adipose. n=5. 
The data are given as the mean ± SEM, and the asterisk indicates p < 0.05. 
Figure 4    Plasma IGF1, IGFBP3 and GH, and hepatic GH signaling and IGF1 and 
IGFBP3 expression in the TBC1D1Ser231Ala knockin mice 
A-C. Plasma levels of IGF1 (A), IGFBP3 (B) and GH (C) in the male wild-type and 
TBC1D1Ser231Ala knockin mice (8-week-old). n=7. 
D. Protein expression and phosphorylation in the liver of the wild-type and TBC1D1Ser231Ala 
knockin mice. 
E. QPCR analysis of igf1 and igfbp3 in the liver of the wild-type and TBC1D1Ser231Ala knockin 
mice. n=6. 
F-G. Quantitation of protein expression of IGF1 (F) and IGFBP3 (G) in the liver. n=6. 
The data are given as the mean ± SEM, and the asterisk indicates p < 0.05. 
Figure 5   IGF1 secretion in primary cells/tissues from the TBC1D1Ser231Ala knockin mice 
A. Co-localisation of TBC1D1 and IGF1 in primary hepatocytes. Bars indicate 10 μm in length. 
B-C. Down-regulation of TBC1D1 in primary hepatocytes via siRNA (B), and IGF1 secretion in 
TBC1D1-depleted primary hepatocytes (C). NC, negative control. n=6. 
D-E. IGF1 secretion, and expression levels of indicated proteins in primary hepatocytes from the 
TBC1D1 knockout mice. n=6. 
F. IGF1 secretion in primary hepatocytes from the TBC1D1Ser231Ala knockin mice. a indicates p < 
0.05 (WT metformin or AICAR vs WT untreated) and b indicates p < 0.05 (KI metformin or 
AICAR vs KI untreated). n=8. 
G. IGF1 secretion in primary chondrocytes from the TBC1D1Ser231Ala knockin mice. a indicates p 
< 0.05 (WT AICAR vs WT untreated) and b indicates p < 0.05 (KI AICAR vs KI untreated). n=6. 
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H. IGF1 secretion in primary adipocytes from the TBC1D1Ser231Ala knockin mice. WT: n=5; KI: 
n=6. 
I. IGF1 secretion in ex vivo EDL muscles from the TBC1D1Ser231Ala knockin mice. WT: n=11; KI: 
n=12. 
J. Phosphorylated and total TBC1D1 and AMPK, and IGF protein levels were measured in 
primary hepatocytes from the TBC1D1Ser231Ala knockin mice using GAPDH as a loading control. 
Met, metformin.  
K. Phosphorylated and total TBC1D1 and AMPK were measured in primary chondrocytes from 
the TBC1D1Ser231Ala knockin mice using GAPDH as a loading control.  
The data are given as the mean ± SEM, and the asterisk indicates p < 0.05 (WT vs KI or KO). 
Statistical analyses for F and G were carried out using two-way ANOVA. 
Figure 6   IGF1 action and activation of the PKB-TSC2-mTOR pathway in primary cells 
from the TBC1D1Ser231Ala knockin mice 
A-C. Phosphorylated and total PKB and mTOR, and phosphorylated TBC1D1 and AMPK were 
measured in AICAR stimulated or unstimulated primary adipocytes from the TBC1D1Ser231Ala 
knockin and wild-type mice using GAPDH as a loading control. A, representative blots; B and C, 
quantified data, n=4.  
D-E. Phosphorylated and total PKB and TBC1D1 were measured in PPP treated or untreated 
primary hepatocytes from the TBC1D1Ser231Ala knockin and wild-type mice using GAPDH as a 
loading control. D, representative blots; E, quantified data, n=6. n.s. not significant. 
The data are given as the mean ± SEM, and the asterisk indicates p < 0.05. Statistical analyses for 
B, C and E were carried out using two-way ANOVA. 
Figure 7   Rab8a and IGF1 secretion in primary hepatocytes 
A. IGF1 secretion, and expression and phosphorylation levels of indicated proteins in TBC1D1 
knockout primary hepatocytes expressing human TBC1D1 (hTBC1D1) wild-type and mutant 
proteins. Ser237 on human TBC1D1 is a paralogous site to Ser231 on the mouse protein. The 
substitution of Arg854 with lysine inactivates the RabGAP of TBC1D1. n=6. 
B-C. Down-regulation of Rab8a in primary hepatocytes via siRNA (B), and IGF1 secretion in 
Rab8a-depleted primary hepatocytes (C). NC, negative control. n=6. 
D. Co-localisation of Rab8a and IGF1 in primary hepatocytes. Bars indicate 10 μm in length. 
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E-F. Down-regulation of Rab8a in primary hepatocytes from the wild-type and TBC1D1Ser231Ala 
knockin mice via siRNA (E), and IGF1 secretion in Rab8a-depleted primary hepatocytes (F). 
n=6. 
G-H. Expression of indicated proteins (G) and IGF1 secretion (H) in TBC1D1 knockout primary 
hepatocytes expressing Rab8a wild-type and mutant proteins. n=6. 
I-J. The GTPase activity of recombinant GST-Rab8a was measured in the presence of 
immunoprecipitated wild-type or R854K mutant hTBC1D1 upon phenformin treatment (I) or in 
the presence of hTBC1D1S237A mutant protein (J). 
K-L. Down-regulation of Rabin8 in primary hepatocytes via siRNA (K), and IGF1 secretion in 
Rabin8-depleted primary hepatocytes (L). NC, negative control. n=6. 
The data are given as the mean ± SEM, and the asterisk indicates p < 0.05. 
 
